Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and existing investors.
Rna Diagnostics is supported by the Ontario Bioscience Innovation Organization (OBIO) through the 2018 Capital Access Advisory Program or CAAP.